
GP at @a16z investing in bio + health | Former biotech founder + operator (CEO, CFO, CSO, CPO) š§¬š§«š§Ŗ | Made in Miami šŗšø šµšŖ šØšŗ
Menlo Park, CA
Joined June 2017
- Tweets2.1K
- Following524
- Followers15.9K
- Likes7.8K
Pinned Tweet
Announcing our newest @a16zBioHealth fund: $700M to back the best founders working to make better medicines and to make the practice of medicine better.
To cure disease, to care for our sick, to fix whatās broken is deeply ingrained; it is medicineās highest aim.
āAt @a16z, we believe that the best thing that a society can do for a person is to give them a chance. Give them a shot at a great lifeā¦ā - @bhorowitz
@vintweeta @julesyoo @BenPortney @Bryan__Faust @zakdoric @JayRughani @daisydwolf @janerheetweets Michael Cialone, Eva Steinman
At Andreessen Horowitz, we just raised over $15B.
With these new funds including American Dynamism ($1.176B), Apps ($1.7B), Bio + Health ($700M), Infrastructure ($1.7B), Growth ($6.75B), and other venture strategies ($3B), we raised over 18% of all venture capital dollars allocated in the United States in 2025.
Why did we raise the money and how do we plan to invest it?
Read more from Ben Horowitz: a16z.news/p/we-raised-15b-whā¦
An expanded @EliLillyandCo + @GeneralMedicine to buld the healthcare store for weight management and memory care š
General Medicine has two announcements with @EliLillyandCo today: GLP-1 weight management on LillyDirect, and a memory care pathway for early Alzheimerās evaluation. Both show what our store can do for a partner, in very different ways.
Weight management is relatively straightforward. But follow-through depends on customers seeing all their options, knowing the price, and having a clinician who understands their whole health picture and goals. We do that.
Memory care is complicated. Figuring out what testing someone has had, what they still need, and how it all fits together is hard. As a result, patients often wait years between their first symptoms and a diagnosis. That delay is particularly consequential for new therapies with a narrow window for treatment.
We bring bloodwork, cognitive testing, imaging, and specialist review together, coordinated by a clinician who knows how to navigate the process. Weāre working to solve one of the biggest bottlenecks in Alzheimerās care, today.
The same store works for both: transparent pricing, clear next steps, and a clinician who helps you get it done.
Thatās the promise of what weāre building @GeneralMedicine: itās simple to get the healthcare you need, no matter how complicated it might be
Weāre excited to work with Lilly to bring both experiences to more people.
19
1,656
Chief of Neurosurgery at @UCSF @EddieChangMD has joined @X and has lots to say.
First up: a newly discovered part of the brain that helps us say what we want to say.
Welcome, Eddie! š§
Each word you say is planned by a small patch of brain above your left ear, about a quarter of a second before you say it. It sits in a temporal lobe region textbooks describe as only for listening. Our paper today in @ScienceMagazine: science.org/doi/10.1126/scieā¦
@UCSF @NeurosurgUCSF
AI is now a consumable reagent for drug discovery: scientists can buy + use intelligence on demand via @boltz_bio molecular tokens.
Molecular token usage up ~50x; deployed at 6 of top 20 pharma.
$110M Series A led by @BessemerVP
@a16z excited to double down!
cc: @zakdoric
Weāve raised $110M to bring AI-powered biomolecular design to every scientist!
Boltzās Series A is led by @BessemerVP, following 50-fold growth in molecular token usage from our users since June and partnerships with 6 of the worldās 20 largest pharma companies.
Jorge Conde retweeted
Excited to launch our first wave of small-molecule chemistry capabilities in Biomni AI co-scientist agent:
- Native molecular editor and viewer
- Expanded tools: OpenFold3 for proteināligand structure prediction, OpenFreeEnergy for binding affinity calculations, REINVENT4 for analog generation, and Chemprop for predictive deep learning models
- Cheminformatics workflows including R-group decomposition and more
This is just the beginning. Let us know what chemistry capabilities youād like to see next!
Amazing work led by @matteo_aldeghi!
Read more: phylo.bio/blog/biomni-for-chā¦
Chemistry is live in Biomni Lab.
Matteo Aldeghi (@matteo_aldeghi) on our science team gave Biomni 803 public COVID Moonshot compounds and asked which series to pursue. It clustered them into 3 candidates, flagged for potency, synthetic accessibility and oral risk, and built a SAR across 18 traceable comparisons.
For the series he picked, Biomni returned a Markush core and a 50-molecule catalogue. The comparisons behind the SAR are traceable, so a chemist can check the reasoning instead of taking the ranking on trust.
Bring a series in at biomni.phylo.bio.
Read Matteo's full write-up here: phylo.bio/blog/biomni-for-chā¦
Jorge Conde retweeted
Congrats to the small but intrepid team of ophtho drug developers at our portfolio company @OllinBio!
ollin.bio/press-releases/ollā¦
The n-of-1 biotech era has arrived.
With @FDAās rare disease framework, n=1 patient receiving a custom medicine?
With AI + @Prof_Oak_, n=1 employee?
n-of-1 can mean your target patient population or your entire org chart.
Congratulations @BenjamineYLiu + the entire @formationbio team on their new $600M fund.
Letās develop all the discovered drugs!
Today weāre announcing the $600M Formation Bio Drug Development Accelerator Fund.
@lintaho and I started @FormationBio because we believed the biggest bottleneck in bringing new medicines to patients wasnāt drug discovery, but drug development.
As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the capital and capacity to advance promising drugs through clinical trials, much of that progress wonāt translate into medicines for patients.
Our new Fund brings together dedicated capital, drug development expertise, and AI-powered development capabilities to acquire promising drugs and advance them through the clinic.
More AI x bio news: @phylo_bio partners with @Bayer to deploy Biomni Lab, Phyloās AI scientist platform.
The vision: Bayer scientists direct teams of Phylo AI agents. Agents learn from and improve based on Bayerās expertise + data, enabling scientists to explore + discover more.
Weāre glad to share our partnership with Bayer to bring Biomni Lab, our frontier AI co-scientist platform, to its scientific research teams. Researchers will harness Biomni Labās agentic capabilities to tackle complex scientific questions, accelerate the path from insight to decision, and scale AI-enabled research workflows across the organization.
Phylo is building toward a future where scientists across the worldās leading life science organizations can direct teams of AI agents to drive new discoveries. This partnership represents a significant step toward realizing that vision.
Read more: phylo.bio/blog/bayer-partnerā¦
Jorge Conde retweeted
BMS scientists have long been part of our open-source community. Now we're building together!
We're excited to bring our latest models together with decades of BMS science, and put better molecular design tools in the hands of the scientists using them.
Today at GTC, weāre excited to announce our collaboration with Bristol Myers Squibb to bring the latest Boltz models into BMSās drug discovery workflows. @bmsnews @boltz_bio šš§µ
Today in AI x bio news: Boltz partners with BMS on small molecules + biologics.
@bmsnews will generate new molecules + optimize existing candidates, and will co-develop custom @boltz_bio AI models informed by BMSās decades of scientific data, insights & expertise.
Today at GTC, weāre excited to announce our collaboration with Bristol Myers Squibb to bring the latest Boltz models into BMSās drug discovery workflows. @bmsnews @boltz_bio šš§µ
Thank you @ashokaraj_ for giving us @a16z the opportunity to part of the @OrchestraBio journey from the very beginning.
cc @JayRughani
Four years ago to the day, we started Orchestra Bio to help biotech and pharma teams advance their drug development programs. AI has now reached an inflection point where people and agents can take this on together. Today, weāre thrilled to share that Orchestra Bio is joining OpenAI to continue our mission at an even greater scale.
Jorge Conde retweeted
Four years ago to the day, we started Orchestra Bio to help biotech and pharma teams advance their drug development programs. AI has now reached an inflection point where people and agents can take this on together. Today, weāre thrilled to share that Orchestra Bio is joining OpenAI to continue our mission at an even greater scale.
Congratulations to @a16z portfolio company @OrchestraBio, @ashokaraj_ + team on joining forces with @OpenAI to help biopharma orchestrate (and accelerate!) the complex journey from scientific discovery to novel medicines for patients!
Doctors, both human and AI, help guide our care.
But once you know what you need, what do you buy? Where do you buy it? How much are you going to pay?
Healthcare needs a store.
@a16z is thrilled to lead @GeneralMedicineās $120m series B @tjparker @elliotcohen @ashwinkmurali
General Medicine has raised a $120M Series B led by @a16z. We're using it to build the healthcare store.
The only way healthcare will work is to make the customer the most powerful participant in the system. And the only way to do that is to let them shop.
Hereās why healthcare needs a store, and what we had to build to make it possible:
āWhat can I do for you today?ā
Why we invested in @GeneralMedicine:
cc: @vintweeta @daisydwolf @evajsteinman
a16z.news/p/investing-in-genā¦
4
441
Jorge Conde retweeted
1) Tuesday 10/6
830-1130am, in SF
(register to see address)
Join @a16z + @EliLillyandCo + @insitro + @BigHatBio + Flex Tx for a set of conversations on what each of these teams are building, both internally and with partners
cc @zakdoric @JorgeCondeBio
partiful.com/e/ccQ8p5st5UNpGā¦



















